Teva launches generic EpiPen Jr.
Teva is offering a generic version of Mylan’s EpiPen Jr., an epinephrine auto-injector in a dosage strength of 0.15 mg. The company previously has launched the adult-dosage generic of EpiPen.
”We’re pleased to provide access to epinephrine injection auto-injector in two strengths for patients who may experience life-threatening allergic emergencies,” said Brendan O’Grady, executive vice president and head of Teva North America commercial. “We will continue working to ensure availability of both strengths in the United States and plan to accelerate production to meet the urgent need for this medicine.”
Teva’s generic of EpiPen and EpiPen Jr. utilize Antares Pharma's Vibex device. Antares and Teva have an exclusive license, development and supply agreement for epinephrine auto-injector products that Teva markets in the United States.
”We’re pleased to provide access to epinephrine injection auto-injector in two strengths for patients who may experience life-threatening allergic emergencies,” said Brendan O’Grady, executive vice president and head of Teva North America commercial. “We will continue working to ensure availability of both strengths in the United States and plan to accelerate production to meet the urgent need for this medicine.”
Teva’s generic of EpiPen and EpiPen Jr. utilize Antares Pharma's Vibex device. Antares and Teva have an exclusive license, development and supply agreement for epinephrine auto-injector products that Teva markets in the United States.